Perspective Therapeutics (CATX) Profit After Tax (2010 - 2026)
Perspective Therapeutics (CATX) posted Profit After Tax of -$26.2 million for Q1 2026, up 30.14% sequentially from -$37.5 million in Q4 2025, and down 44.08% YoY from -$46.8 million in Q1 2025.
Perspective Therapeutics (CATX) Profit After Tax (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Profit After Tax for 17 years, with the latest figure at -$26.2 million in Q1 2026.
- Quarterly Profit After Tax fell 44.08% year-over-year to -$26.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$111.0 million (down 30.35% YoY) and the FY2025 annual result came in at -$103.1 million, down 30.07% from the prior year.
- Profit After Tax advanced to -$26.2 million in Q1 2026 per CATX's latest filing, from -$37.5 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$371000.0 in Q1 2023 and troughed at -$40.2 million in Q4 2024.
- A 5-year average of -$16.2 million and a median of -$12.3 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 72.46% in 2023, then plunged 3211.05% in 2024.
- Over 5 years, Profit After Tax stood at -$7.3 million in 2022, then sank by 236.4% to -$24.7 million in 2023, then plunged by 62.79% to -$40.2 million in 2024, then grew by 6.67% to -$37.5 million in 2025, then soared by 30.14% to -$26.2 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$26.2 million, -$37.5 million, and -$25.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 241.90 Mn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | 573.00 Mn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 619.54 Mn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Perspective Therapeutics | 384.88 Mn | 384.88 Mn | - | -26.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.79 Mn |
| Mar 31, 2026 | -26.19 Mn |
| Dec 31, 2025 | -37.49 Mn |
| Sep 30, 2025 | -25.86 Mn |
| Jun 30, 2025 | -21.49 Mn |
| Mar 31, 2025 | -18.18 Mn |
| Dec 31, 2024 | -40.17 Mn |
| Sep 30, 2024 | -15.12 Mn |
| Jun 30, 2024 | -11.70 Mn |
| Mar 31, 2024 | -12.28 Mn |
| Dec 31, 2023 | -24.68 Mn |
| Sep 30, 2023 | -10.36 Mn |
| Jun 30, 2023 | -11.11 Mn |
| Mar 31, 2023 | -371,000.00 |
| Dec 31, 2022 | -7.34 Mn |
| Sep 30, 2022 | -7.87 Mn |
| Jun 30, 2022 | -3.71 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -1.60 Mn |
| Sep 30, 2021 | -2.24 Mn |